期刊文献+

枸橼酸局部抗凝在血液滤过治疗中的应用研究 被引量:11

下载PDF
导出
摘要 目的通过比较枸橼酸局部抗凝(RCA)与无肝素抗凝(NH)在血液滤过治疗中抗凝作用,来证实枸橼酸局部抗凝有效性及安全性。方法选择20例有高危出血风险行血液滤过治疗(CVVH)病例,治疗46例次,随机分为2组,一组采用枸橼酸局部抗凝,即RCA组(n=24),一组采用无肝素生理盐水冲管抗凝,即NH组(n=22)。观察并比较RCA组治疗开始时、2h、4h、8h、治疗结束时体内血和管路血iCa2+、PT、APTT的变化;监测RCA组治疗开始时、2h、4h、8h、治疗结束时病人体内血pH、HCO3-、Na+;比较两组管路滤器寿命。结果 RCA组治疗开始时、2h、4h、8h、治疗结束时管路血iCa2+均较病人体内血iCa2+明显降低(P<0.05),管路血PT、APTT均较病人体内血PT、APTT明显延长(P<0.05),病人体内血iCa2+、PT、APTT无变化(P>0.05);病人体内血pH、HCO3-、Na+无显著变化(P>0.05);RCA组管路滤器寿命明显长于NH组,为18.5±6.2h对4.9±1.9h(P<0.01)。结论枸橼酸局部抗凝通过降低管路血iCa2+延长管路血PT、APTT,从而达到延长管路滤器寿命的目的 ;枸橼酸局部抗凝对病人体内血PT、APTT、pH、HCO3-、Na+无影响。
出处 《江西医药》 CAS 2011年第2期153-155,共3页 Jiangxi Medical Journal
  • 相关文献

参考文献6

  • 1Bellomo R,Ronco C(1988).Continuous versus intermittent renal replacement therapy in the intensive care unit.Kidney Int,53(S66): S125. 被引量:1
  • 2王质刚主编..血液净化学[M].北京:北京科学技术出版社,2003:1110.
  • 3龚德华,季大玺,徐斌,谢红浪,刘云,黎磊石.在严重出血倾向重危患者应用枸橼酸抗凝进行连续性静脉-静脉血液滤过治疗[J].肾脏病与透析肾移植杂志,2002,11(6):510-514. 被引量:39
  • 4Cardigan RA, McGloin H, Mackie IJ.Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration.Kidney, Int, 1999,55 : 1568. 被引量:1
  • 5Jannsen MJFM,Huijgens PC ,Bouman AA,et al. Citrate versus heparin anticoagulation in chronic hemodialysis patients. Nephrol Didl Transplant, 1993,8:1228. 被引量:1
  • 6Palsson R, Niles JL.Regional citrate anticoagulation in continuous venovenous hemodiafitration in critically ill patients with a high risk of bleeding.Kidney Int, 1999,55 : 1991. 被引量:1

二级参考文献16

  • 1Palsson R,Niles JL.Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding.Kidney Int,1999,55:1991 被引量:1
  • 2Tolwani JA,Campbell RC,Schenk MB et al.Simplified citrate anticoagulation for continuous renal replacement therapy.Kidney Int,2001,60:370 被引量:1
  • 3Janssen MJ,Huijgens PC,Bouman AA et al.Citrate versus heparin anticoagulation in chronic hemodialysis patients.Nephrol Dial Transplant,1993,8(11):1228 被引量:1
  • 4Kirschbaum B,Galishoff M,Reines HD.Lactic acidosis treated with continuous hemodiafiltration and regional citrate anticoagulation.Crit Care Med,1992,20(3):349 被引量:1
  • 5Meulen JVD,Janssen MJFM,Langendijk PNJ et al.Citrate anticoagulation and dialysate with reduced buffer content in chronic hemodialysis.Clin Nephrol,1991,37(1):36 被引量:1
  • 6Kutsogiannis DJ,Mayers I,Chin WDN et al.Regional citrate anticoagulation in continuous venovenous hemodiafiltration.Am J Kidney Dis,2000,35(5):802 被引量:1
  • 7Oberbauer R,Fabrizii V,Drumal W et al.Acute acid-base disorder during plasma immunoadsorption treatment using citrate anticoagulation.Nephrol Dial Transplant,1998,13(6):1581 被引量:1
  • 8Sramek V,Novk I,Matějovi M et al.Continuous venovenous hemodiafiltation (CVVHDF) with citrate anticoagulation in the treatment of a patient with acute renal failure,hypercalcemia,and thrombocytopenia.Intens Care Med,1998,24:262 被引量:1
  • 9Dhondt A,Vanholder R,Tielemans C et al.Effect of regional citrate anticoagulation on leukopenia,complement activation,and expression of leukocyte surface molecules during hemodialysis with unmodified cellulose membranes.Nephron,2000,85(4):334 被引量:1
  • 10Bohler J,Schollmeyer P,Dressel B et al.Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation:Dissociation of complement activation and neutropenial from neutrophil degranulation.J Am Soc Nephrol,1996,7:234 被引量:1

共引文献38

同被引文献112

引证文献11

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部